|
rs16902094
|
|
|
0.720 |
GeneticVariation |
BEFREE |
A statistically significant interaction was observed for each of 2 SNPs in the 8q24 region (rs620861 and rs16902094), 25(OH)D concentration, and fatal prostate cancer on both multiplicative and additive scales (P ≤ 0.001).
|
28399564 |
2017 |
|
rs16902094
|
|
|
0.720 |
GeneticVariation |
BEFREE |
These included correlations between an intergenic CpG site at Chr8:128393157 and the prostate cancer SNP rs16902094 (ρ = -0.54; P = 9.7 × 10(-7); q = 0.002), a PRNCR1 CpG site at Chr8:128167809 and the prostate cancer SNP rs1456315 (ρ = 0.52; P = 1.4 × 10(-6); q = 0.002), and two POU5F1B CpG sites and several prostate/colorectal cancer SNPs (for Chr8:128498051 and rs6983267, ρ = 0.46; P = 2.0 × 10(-5); q = 0.01).
|
25315430 |
2014 |
|
rs378854
|
|
|
0.010 |
GeneticVariation |
BEFREE |
This approach identified rs378854, which is in complete linkage disequilibrium (LD) with rs620861, as a novel functional prostate cancer-specific genetic variant.
|
21814516 |
2011 |
|
rs72725854
|
|
|
0.710 |
GeneticVariation |
BEFREE |
The 8q24 risk region was also found to be a major contributor to PCa risk in Ugandan men, with the African ancestry-specific risk variant rs72725854 estimated to account for 12% of PCa in this population.
|
29356057 |
2018 |
|
rs16901979
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Two of these 17 SNPs, located at 3p12, and region 2 at 8q24, were significantly associated with prostate cancer risk (P < 0.05), and only SNP rs16901979 at region 2 of 8q24 remained significant after accounting for 20 tests.
|
19549807 |
2009 |
|
rs16901979
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Therefore, this meta-analysis demonstrated that 8q24 polymorphisms (rs6983267 T>G, rs1447295 C>A, rs16901979 C>A, rs6983561 A>C and rs10090154 C>T) were associated with the susceptibility to PCa, which held the potential biomarkers for PCa risk.
|
29158792 |
2017 |
|
rs16901979
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The variants rs16901979 and rs6983561 at 8q24 are associated with prostate cancer risk in Taiwanese men.
|
19908238 |
2010 |
|
rs16901979
|
|
|
0.800 |
GeneticVariation |
BEFREE |
A meta-analysis across 10 studies including our results of four 8q24 variants (rs1442295 and DG8S737-region 1, rs16901979-region 2, and rs6983267-region 3) and prostate cancer risk demonstrated strong associations across a wide array of study designs and populations.
|
18231127 |
2008 |
|
rs16901979
|
|
|
0.800 |
GeneticVariation |
BEFREE |
In particular, both homozygous AA and heterozygous CA genotypes of rs16901979, as well as the AA and CA genotypes of rs1447295, were associated with the risk of prostate cancer.
|
30061842 |
2018 |
|
rs16901979
|
|
|
0.800 |
GeneticVariation |
BEFREE |
There was no joint effect between SNPs rs16901979 A and rs6983267 G. These results confirm the significance of these SNPs in prostate cancer etiology in a previously unstudied population who do not undergo prostate cancer screening and are diagnosed with severe disease.
|
18768513 |
2008 |
|
rs16901979
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Forty-nine tagging SNPs including three previously reported significant variants (rs1447295, rs6983267, rs16901979) and seven variants in the 5' upstream region of the MYC proto-oncogene were tested for association with susceptibility to PC and tumor aggressiveness in 596 histologically verified PC cases and 567 ethnically matched controls.
|
19562729 |
2009 |
|
rs16901979
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Significant differences (P < 0.00185) between the two subtypes were observed for rs16901979 (8q24) and rs1859962 (17q24), which were enriched in TMPRSS2:ERG fusion-negative (OR = 0.53, P = 0.0007) and TMPRSS2:ERG fusion-positive PrCa (OR = 1.30, P = 0.0016), respectively.
|
27798103 |
2016 |
|
rs16901979
|
|
|
0.800 |
GeneticVariation |
BEFREE |
In summary, the A allele at rs16901979 was associated with the risk of prostate cancer in the Caribbean population of Guadeloupe, confirming its involvement in populations of African descent.
|
25130587 |
2016 |
|
rs16901979
|
|
|
0.800 |
GeneticVariation |
BEFREE |
In conclusion, this is the first study showing that prostate cancer risk variants, such as rs16901979, might improve outcome prediction following ADT, thus allowing identification of high-risk patients who might benefit from appropriate adjuvant therapy.
|
21445969 |
2012 |
|
rs16901979
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We demonstrate that trans-acting RNA molecules facilitating resistance to androgen depletion (RAD) in vitro and castration-resistant phenotype (CRP) in vivo of PC contain intergenic 8q24-locus SNP variants (rs1447295; rs16901979; rs6983267) that were recently linked with increased risk of PC.
|
22067658 |
2011 |
|
rs16901979
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The rs16901979 CA genotype carriers had a higher risk of prostate cancer than the CC genotype.
|
22583965 |
2012 |
|
rs16901979
|
|
|
0.800 |
GeneticVariation |
BEFREE |
SNPs rs6983561, rs7008482, and rs16901979 were significantly associated with CaP risk in WAs (P < 0.03).
|
22234922 |
2012 |
|
rs16901979
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We report that rs7008482, which maps to the 8q24.13 region, is an additional independent prostate cancer risk variant (P = 5 x 10(-4)), and we also replicate the association of rs16901979 with prostate cancer (P = 0.002).
|
17978284 |
2007 |
|
rs16901979
|
|
|
0.800 |
GeneticVariation |
BEFREE |
SNP rs16901979 in region 2 was associated with significantly increased risk of prostate cancer (OR = 1.41, 95% confidence interval [CI] 1.02-1.95, P = 0.04) with the risk stronger in men with early-onset prostate cancer (OR = 2.37, 95% CI 1.40-3.99, P = 0.001).
|
21557270 |
2011 |
|
rs16901979
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Three 8q24 polymorphisms (rs1447295 C>A, rs16901979 C>A, and rs6983267 T>G) have been extensively investigated for their association with prostate cancer (PCa) susceptibility, yet conclusions are contradictory.
|
26159557 |
2015 |
|
rs16901979
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The results of the meta-analyses indicate that rs6983267, rs1447295, rs6983561, rs7837688, rs16901979, and DG8S737 are significantly associated with a higher risk for PCa for at least one race, whereas the variants rs13254738 and rs7000448 are not.
|
22382457 |
2012 |
|
rs6983561
|
|
|
0.780 |
GeneticVariation |
BEFREE |
Notably, rs6983561 was significantly associated with prostate cancer among men diagnosed at an early (<50 years) but not later age (p = 0.03 versus p = 0.21).
|
18360876 |
2008 |
|
rs6983561
|
|
|
0.780 |
GeneticVariation |
BEFREE |
In the Japanese population examined in this study, the rs6983561 polymorphism at 8q24 was significantly associated with prostate cancer mortality, especially among patients with metastatic disease.
|
21700508 |
2011 |
|
rs6983561
|
|
|
0.780 |
GeneticVariation |
BEFREE |
Of the 82 known risk variants, 68 (83%) had effects that were directionally consistent in their association with prostate cancer risk and 30 (37%) were significantly associated with risk at p < 0.05, with the most statistically significant variants being rs116041037 (p = 3.7 × 10(-26) ) and rs6983561 (p = 1.1 × 10(-16) ) at 8q24, as well as rs7210100 (p = 5.4 × 10(-8) ) at 17q21.
|
25044450 |
2015 |
|
rs6983561
|
|
|
0.780 |
GeneticVariation |
BEFREE |
Furthermore, the SNPs rs6983561 and rs4430796 were associated with a susceptibility to aggressive prostate cancer, whereas rs1859962 was associated with non-aggressive prostate cancer.
|
21557267 |
2011 |